PanGenomic Health, Inc. Class A (NARA) AI Stock Analysis

Top Page

PanGenomic Health, Inc. Class A

(CNQX:NARA)

Select Model

Rating:42Neutral

Price Target:CAD 0.15▼(-9.41% Downside)

Action:reiterated

Date:10/11/26

The score is primarily held down by very weak financial performance (no revenue, widening losses, ongoing cash burn, and negative equity). Technicals add further pressure with the price below all key moving averages and negative MACD, while valuation is difficult to assess due to negative earnings and no provided dividend yield.

Positive Factors

Moderate absolute debtDebt of about $0.72M TTM is moderate in absolute dollars and has not been consistently high across years. That limits, but does not remove, leverage pressure; relative debt restraint could preserve some flexibility if operations improve or financing becomes available.

Negative Factors

No revenue generationZero reported revenue alongside consistently negative gross profit indicates the core business has not yet demonstrated commercial traction. Without sales, the company lacks an operating base to absorb costs, validate demand, or support durable margin expansion over the coming quarters.

PanGenomic Health, Inc. Class A (NARA) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 2.39M
Dividend Yield: ―
Average Volume (3M): 15.24K
Price to Earnings (P/E): -0.8
Beta (1Y): -0.09
Revenue Growth: ―
EPS Growth: 43.30%
Country: Canada
Employees: 0
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Information Services

PanGenomic Health, Inc. Class A Business Overview & Revenue Model

Company Description

Pangenomic Health Inc. is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments to support mental health. The company's mobile app, the Nara App, provid...

PanGenomic Health, Inc. Class A Financial Statement Overview

Summary

Weak fundamentals: the company reports no revenue, negative gross profit, widening net losses into TTM (about -$4.25M), and sustained cash burn (operating cash flow about -$2.21M TTM). The balance sheet is constrained by negative shareholders’ equity (about -$2.75M TTM) and a very small asset base, increasing financing and execution risk despite debt not being extreme in absolute terms.

Income Statement

6Very Negative

Balance Sheet

12Very Negative

Cash Flow

8Very Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Jun 2025	Jun 2024	Mar 2023	Dec 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	-629	-628	―	-681.43K	-11.11K	-2,127
EBITDA	-4.23M	-3.42M	7,410	-2.71M	-3.57M	-847.50K
Net Income	-4.25M	-3.43M	-3,803	-2.97M	-20.35M	-2.65M
Balance Sheet
Total Assets	157.72K	160.91K	39.16K	71.48K	504.14K	2.58M
Cash, Cash Equivalents and Short-Term Investments	7,717	38.77K	1,307	12.56K	88.53K	1.35M
Total Debt	715.34K	212.87K	0	964.75K	101.77K	0
Total Liabilities	2.91M	2.35M	2.44M	2.22M	719.25K	334.45K
Stockholders Equity	-2.75M	-2.19M	-2.41M	-2.14M	-215.11K	2.24M
Cash Flow
Free Cash Flow	-2.21M	-1.88M	-58.25K	-1.57M	-2.79M	-1.07M
Operating Cash Flow	-2.21M	-1.88M	-58.25K	-1.57M	-2.78M	-1.06M
Investing Cash Flow	0	0	0	-3,142	-52.13K	-604.91K
Financing Cash Flow	2.21M	1.92M	47.00K	1.50M	1.57M	2.97M

PanGenomic Health, Inc. Class A Technical Analysis

Technical Analysis SentimentNegative

Last Price0.17

Price Trends

50DMA0.25Negative

100DMA0.29Negative

200DMA0.36Negative

Market Momentum

MACD-0.03Negative

RSI31.86Neutral

STOCH66.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NARA, the sentiment is Negative. The current price of 0.17 is below the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.25, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 31.86 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:NARA.

PanGenomic Health, Inc. Class A Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:NARA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:NDAT	45Neutral	CAD 2.89M	-16.67	-49.83%	―	―	0.00%
TSE:AIDR	44Neutral	CAD 44.56M	-1.64	-444.52%	―	415.06%	-54.80%
TSE:NARA	42Neutral	CAD 2.39M	-0.82	184.91%	―	―	43.30%
TSE:UDOC	41Neutral	CAD 5.18M	-1.59	355.56%	―	614.03%	51.97%
TSE:ADK	40Underperform	CAD 40.34M	-8.11	9999.00%	―	-36.92%	13.03%
TSE:DMED	39Underperform	CAD 3.95M	-1.94	739.84%	―	―	-28.35%

* Healthcare Sector Average

Performance Comparison

TSE:NARA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:NARA	PanGenomic Health, Inc. Class A	0.17	-1.03	-85.83%
TSE:ADK	Diagnos Inc	0.34	-0.01	-1.47%
TSE:NDAT	nDatalyze Corp	0.07	0.06	366.67%
TSE:AIDR	Rocket Doctor Ai Inc	0.44	-0.44	-50.00%
TSE:UDOC	Unidoc Health Corp.	0.06	-0.13	-68.42%
TSE:DMED	DiagnaMed Holdings Corp.	0.03	-0.06	-66.67%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 11, 2026

PanGenomic Health, Inc. Class A AI Stock Analysis

Top Page